Other News To Note
• Santhera Pharmaceuticals AG, of Liestal, Switzerland, said it obtained an exclusive license from the National Institutes of Health (NIH) to rights on a patent granted in the U.S. for the use of idebenone for the treatment of primary aggressive multiple sclerosis.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter